Study Title
Subjects will be treated in cohorts at three sequential target absorbed radiation dose levels, where the dose level for the next cohort will be determined by a prespecified decision tree for escalation/de-escalation, according to the accelerated Time-to-Event Bayesian Optimal Interval Design (TITE-BOIN) approach.
Study Details
Description:
The VOYAGER Study is an interventional, non-randomized, single-arm, dose escalation trial with the goal of determining the safety of TheraSphere PCa device in patients with clinically localized prostate cancer across US-based centers.
Sponsor:
Boston Scientific Corporation
Contacts:
McAnthony Tarwaymcanthony.tarway@bsci.com
615-580-1320
Shirley Nyepahshirley.nyepah@bsci.com
612-300-7205
Government Study Link:
NCT06192758 - Click here to see study onClinicalTrials.gov
